Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Clinical trial NCT03578198 · TERMINATED

Trial details

NCT number: NCT03578198
Sponsor: Seoul National University Hospital
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

CD20-positive Non-Hodgkin Lymphoma

Start date: 2018-11-08
Primary completion: 2022-04-07
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.